Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783536 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2AMEN1LMNARXRA | |
| SCHEMBL6783870 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AMEN1LMNARXRA | |
| SCHEMBL6784162 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMEN1LMNARXRA | |
| SCHEMBL8361367 | 0.78 | NOTUM (0.47) | KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL8361365 | 0.78 | NOTUM (0.47) | KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL8361363 | 0.78 | NOTUM (0.47) | KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL8364187 | 0.77 | MAOA (0.52) | KMT2AMEN1 | |
| SCHEMBL8364186 | 0.77 | MAOA (0.52) | KMT2AMEN1 | |
| SCHEMBL8364183 | 0.77 | MAOA (0.52) | KMT2AMEN1 | |
| SCHEMBL7943800 | 0.71 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | SMN1; SMN2 62/4885KMT2A 490/4885MEN1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.